Omni Bio Pharm Inc (OMBP) 0.2300 $OMBP
Omni Bio to Present at 7th Annual BioPharm America Conference
Marketwire - Tue Sep 16, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"
, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today that it will present at the 7th Annual BioPharm America(TM) 2014 conference, September 22-24, held at the Boston Marriott Copley Place in Boston, MA.
Omni Bio Appoints Jack Riccardi as Chief Financial Officer
Marketwire - Thu Aug 14, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio" , an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014.
Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.
Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013.
Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD" .
Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT.
Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013.
Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider.
Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio" (OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009.
Omni Bio to Present at 7th Annual BioPharm America Conference
Marketwire - Tue Sep 16, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"
, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today that it will present at the 7th Annual BioPharm America(TM) 2014 conference, September 22-24, held at the Boston Marriott Copley Place in Boston, MA. Omni Bio Appoints Jack Riccardi as Chief Financial Officer
Marketwire - Thu Aug 14, 8:03AM CDT
Omni Bio Pharmaceutical, Inc. (PINKSHEETS: OMBP) ("Omni Bio"
, an emerging biopharmaceutical company focused on revolutionizing the treatment of immune-mediated inflammatory diseases, announced today the appointment of Jack Riccardi as its Chief Financial Officer. Mr. Riccardi brings more than 30 years of financial leadership experience. He was formerly CFO of ADial Pharmaceuticals and served most recently as CFO and Partner at Green Street Ventures. Mr. Riccardi's appointment will become effective on September 1, 2014. Omni Bio Pharmaceutical Inc appoints Sandra J. Wrobel to board
M2 - Thu Jul 18, 6:31AM CDT
Biopharmaceutical company Omni Bio Pharmaceutical Inc (OTCBB:OMBP) reported on Wednesday the election of Sandra J. Wrobel MBA to its board of directors, with effect from 15 July 2013.
Omni Bio Pharmaceutical Appoints Ms. Sandra Wrobel as New Director
Marketwire - Wed Jul 17, 3:00PM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Ms. Sandra J. Wrobel, MBA, to its Board of Directors, effective July 15, 2013. Omni Bio Announces Support for Clinical Trial of Graft vs Host Disease
Marketwire - Wed Jul 10, 8:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced its financial support for a clinical trial of AAT for the treatment of complications following bone marrow transplantation, commonly referred to as Graft versus Host Disease ("GvHD" . Omni Bio Announces First Results for Its Lead Recombinant Molecule
Marketwire - Fri Mar 15, 7:00AM CDT
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, today announced the first disclosure of important results for its recombinant molecule, Fc-AAT. Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director
Marketwire - Wed Feb 06, 8:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of next-generation recombinant forms of AAT, today announced the appointment of Michael E. Kamarck, Ph.D., to its Board of Directors, effective January 31, 2013. Omni Bio Pharmaceutical CEO Provides Company Update
Marketwire - Thu Jan 31, 8:00AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the commercialization of alternative uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today provided a company update from its new CEO, Dr. Bruce E. Schneider. Omni Bio Pharmaceutical Appoints New CEO
Marketwire - Thu Dec 20, 7:01AM CST
Omni Bio Pharmaceutical, Inc. ("Omni Bio"
(OTCBB: OMBP), a biopharmaceutical company focused on the development of alternative uses of Alpha-1 antitrypsin (AAT) for the treatment of a variety of indications and the development of recombinant forms of AAT, today announced the appointment of Bruce E. Schneider, PhD, as its Chief Executive Officer, effective January 1, 2013. Dr. Schneider will also become a member of the Company's board of directors. In addition to this appointment, Omni Bio announced that it has engaged Bruce D. Forrest, MD, through B D Forrest & Company, Inc., as a consultant in the areas of product and business development. Both Dr. Schneider and Dr. Forrest are former executives at Wyeth, which was acquired by Pfizer in 2009. 
